An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment

NCT03335540 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: Relatlimab
BIOLOGICAL: Cabiralizumab
BIOLOGICAL: Ipilimumab
DRUG: IDO1 Inhibitor
RADIATION: Radiation Therapy

Sponsor

Bristol-Myers Squibb